# 2026-08455: FDA Yanks Drug Approval: Lies and Lies in Medicine's Pipeline?

2026-08455, ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-30, effective The applicant may submit a written request for a hearing by June 1, 2026 and submit all data, information, and analyses in support of the hearing request by June 29, 2026. Others may submit electronic or written comments by June 29, 2026.; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-08455
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-08455
- Title: ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 23278
- Published: 2026-04-30
- Effective: The applicant may submit a written request for a hearing by June 1, 2026 and submit all data, information, and analyses in support of the hearing request by June 29, 2026. Others may submit electronic or written comments by June 29, 2026.
- Comments close: 2026-06-29
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Yanks Drug Approval: Lies and Lies in Medicine's Pipeline?

## Summary

The FDA wants to take back its approval of the drug TAVNEOS, made by ChemoCentryx, because new info shows it might not work as promised and some facts in the application weren’t true. ChemoCentryx can ask for a hearing by June 1, 2026, to defend their drug. This could affect patients using TAVNEOS and might shake up the company’s plans and finances.

## Abstract

The Food and Drug Administration's (FDA, Agency, or we) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of the new drug application (NDA) for TAVNEOS (avacopan) capsule, 10 milligrams (mg), held by ChemoCentryx, Inc., One Amgen Center Dr., Thousand Oaks, CA 91320 (ChemoCentryx or applicant), and is announcing an opportunity for the applicant to request a hearing on this proposal. The grounds for the proposal are twofold: (i) on the basis of new information before FDA, evaluated together with the evidence available to FDA when the application was approved, there is a lack of substantial evidence that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its labeling; and (ii) the application contains untrue statements of material fact.

## Effects PRIA read

- FDA Proposes Withdrawal of TAVNEOS Approval: mixed, high. The FDA is proposing to withdraw approval of TAVNEOS (avacopan) capsule, 10 mg, which the agency originally approved on October 7, 2021 for adjunctive treatment of adult patients with severe active ANCA-associated vasculitis. The agency's grounds are that new information shows manipulated study dat…
- Postmarket Safety Signals: Liver Risks: cost, high. FDA identified hepatotoxicity as a key safety risk for avacopan and noted serious and sometimes fatal hepatotoxicity cases reported after approval. Recent postmarketing safety reports also suggest avacopan may be associated with vanishing bile duct syndrome (VBDS), an unexpected serious adverse eve…
- Hearing and Comment Deadlines Set: benefit, low. ChemoCentryx (the applicant) may request a hearing on the proposed withdrawal by June 1, 2026, and must submit all data and analyses supporting a hearing request by June 29, 2026. Other interested parties may submit electronic or written comments by June 29, 2026.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-08455 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/30/2026-08455/chemocentryx-inc-proposal-to-withdraw-approval-of-new-drug-application-for-tavneos-avacopan-capsule)
- [2026-08455 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-30/pdf/2026-08455.pdf)

## Related
- [Previous: 2026-08454, New England Fishery Management Council; Public Meeting](https://policyrisk.com/federal-register/2026-08454)
- [Next: 2026-08456, Proposed Collection; 60-Day Comment Request; NIH Office of Intramural Training…](https://policyrisk.com/federal-register/2026-08456)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-08455 (as of 2026-06-08).
